Episodes

Francine Foss, MD and John A. Zic, MD, MMHC Recorded on March 28, 2022 This informative episode covers everything you need to know about cutaneous T-cell lymphoma, from its biology, subclassifications, targeted therapy, goals of treatment, novel toxicities, and so much more! Join Dr. Ken Miller as he delves into cutaneous T-cell lymphoma with two special guests; Dr. Francine Foss from Yale University School of Medicine and Dr. John Zic from Vanderbilt University Medical Center. Learn more abou...

Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center, Houston, TX Recorded on February 18, 2022 Srdan Verstovsek, MD, PhD Professor of Medicine Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms Department of Leukemia MD Anderson Cancer Center Houston, TX In this month’s episode, Dr. Srdan Verstovsek, from MD Anderson Cancer Center in Houston, Texas, joins us to discuss myelofibrosis. What is myelofibrosis? What is our understanding of the disease? What...

Jacqueline C. Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY Recorded on February 1, 2022 Jacqueline C. Barrientos, MD, MS Professor of Medicine Zucker School of Medicine at Hofstra/Northwell CLL Research & Treatment Program Hempstead, NY Shared decision making between patients and their healthcare team is an important component to treatment, regardless of the diagnosis. For chronic leukemias, patient worries may be intensified when doctors suggest forgo...

Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on January 4, 2022 Caron Jacobson, MD Assistant Professor of Medicine Harvard Medical School Medical Director Immune Effector Cell Therapy Program Dana-Farber Cancer Institute Boston, MA As we move into 2022, chimeric antigen receptor (CAR) T-cell therapy continues to be a very exciting and effective treatment option for some blood cancer patients. In this episode, Dr. Caron Jacobson, Assistant Professor of Medicine, ...

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 22, 2021 Each year, blood cancer professionals gather at the American Society of Hematology Annual Meeting to discuss the latest updates in blood cancer research, treatment, and clinical trials. In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, highlights the inflection points from the 63rd ASH Annual Meeting, including CAR T-cell...

John P. Leonard, MD, Weill Cornell Medicine, New York Presbyterian, New York, NY Recorded on December 16, 2021 As 2021 comes to a close, the COVID-19 pandemic continues to evolve. In this episode, Dr. John Leonard, from Weill Cornell Medicine, New York Presbyterian Hospital, discusses the latest updates on how COVID-19 affects the blood cancer patient population. What is the value of the vaccine in blood cancer patients who are on treatment that diminishes immune response? What are the risks a...

Maria Alma Rodriguez, MD, MACP, CMQ, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on October 21, 2021 In this episode, Dr. Maria Alma Rodriguez from The University of Texas MD Anderson Cancer Center, joins us in discussing the long-term and late effects of cancer treatment, including strategies to support survivors with physical and psychosocial effects. Dr. Rodriguez describes barriers to follow-up care, including why some patients may be lost to this process, chall...

Daniel Verina, DNP, ACNP-BC, Mount Sinai Medical Center, New York, NY Recorded on October 1, 2021 Advanced practice providers, nurses, and other members of the multidisciplinary healthcare team play an important role in treating and supporting newly diagnosed myeloma patients. In this month’s episode, Daniel Verina, DNP, ACNP-BC, Acute Care Nurse Practitioner, Multiple Myeloma Program, at the Mount Sinai Medical Center in New York, shares his perspective into treating newly diagnosed myeloma p...

Joshua Richter, MD, Icahn School of Medicine at Mount Sinai, New York, NY Recorded on September 10, 2021 Treating myeloma patients, especially newly diagnosed, can be very complex. How are treatment decisions determined? Who is eligible to receive a transplant? What is the patient’s role in making treatment decisions? In this month’s episode, Dr. Joshua Richter from the Icahn School of Medicine at Mount Sinai Hospital in New York, provides his perspective on treating newly diagnosed myeloma pa...

Lorenzo Falchi, MD and Leah Szumita, MS, RN, CCRN, ACNS-BC Recorded on August 5, 2021 Clinical trials are the foundation of advancing treatment options. Understanding their importance, dispelling myths and fears about enrollment, and acknowledging disparities in access can help providers educate their patients and discuss treatment in a clinical trial as an option at any point in the patient’s cancer journey. In this episode, we welcome special guest host Leah Szumita, MS, RN, CCRN, ACNS-BC, D...

David Tate, BSN, RN, PHN, Rio Bravo-Greeley School, Bakersfield, CA Recorded on August 11, 2021 September is Childhood Cancer Awareness Month, a time to recognize the children and families affected by blood cancer. In this month’s special episode, we are joined by David Tate, a registered nurse in the Rio Bravo-Greeley School system in Bakersfield, California to discuss his journey from the father of a cancer survivor to healthcare professional. David shares with us the story of his son’s diag...

Justine M. Kahn, MD, MS, Columbia University Irving Medical Center, New York, NY Recorded on July 13, 2021 Healthcare disparities are a known factor in cancer care. Understanding these disparities can enable healthcare professionals to more effectively communicate with and treat their patients. In this episode, Dr. Justine Kahn, from the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center in New York City, defines and describes existing healthcare disparitie...

Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on June 18, 2021 Tune in to this very informative and interesting conversation on T-cell lymphoma! Dr. Steven Horwitz, from Memorial Sloan Kettering Cancer Center in New York City, discusses types and diagnostic tests used to identify T-cell lymphoma, goals of treatment, approved and emerging treatment options, including immunotherapy and clinical trials, strategies to manage side effects, including when to stop ...

Jeffrey L. Wolf, MD, University of California San Francisco, San Francisco, CA Recorded on May 27, 2021 In this episode, Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what measurable residual disease (MRD) is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community,...

Justin M. Watts, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL Recorded on May 14, 2021 Terminology, available tests, the impact of epigenetics, and the significance of mutations. Understanding the role of genomics in cancer care can be complex. Tune in as Dr. Justin Watts from the Sylvester Comprehensive Cancer Center in Miami, breaks down cancer genomics, discusses the implications of treatment, outlines the various tests available, including their strengths and w...

Peter Campbell, PharmD, BCOP, Columbia University Irving Medical Center, New York, NY Recorded on April 23, 2021 The interprofessional oncology team is comprised of many healthcare professionals, each playing an important role in contributing to a patient’s care. Join Dr. Peter Campbell, Clinical Pharmacy Manager from Columbia University Irving Medical Center, as he discusses the vital role of pharmacists on the multidisciplinary team. Dr. Campbell discusses challenges with access to treatment...

Edward A. Stadtmauer, MD, The University of Pennsylvania, Philadelphia, PA Recorded on February 23, 2021 In recognition of March being Myeloma Awareness Month, The Leukemia & Lymphoma Society is pleased to share this informative podcast episode on updates and advancements in multiple myeloma. Healthcare professionals are challenged to stay up-to-date on new and emerging treatments options, including updates in immunotherapy, and to incorporate these treatment approaches into decision making. D...

Michael Angarone, DO, FIDSA, Feinberg School of Medicine, Chicago, IL Recorded on February 25, 2021 There are so many questions cancer patients and their families have about the COVID-19 vaccine. What are the differences between the vaccines available? How do they work? Who should get vaccinated? Can one resume activities once vaccinated? This important podcast episodes aims to dispel myths surrounding the COVD-19 vaccine and reiterate its safety for oncology patients, their families, and heal...

Sonali M. Smith, MD, FASCO, The University of Chicago, Chicago, IL Recorded on January 25, 2021 How do we start the conversation? How do we discuss patient expectation and the likelihood of relapse? What role does the timing of relapse play? In this episode, Dr. Sonali Smith, the Elwood V. Jensen Professor of Medicine at The University of Chicago, discusses expectations for disease control and for relapse, the mechanisms of resistance, exciting advances in the treatment of relapsed/refractory ...

Olatoyosi Odenike, MD and Wendy Stock, MD Recorded on January 15, 2021 Join Drs. Wendy Stock and Olatoyosi Odenike from The University of Chicago Medicine, in an important discussion on the progress in the treatment of acute myeloid leukemia, including important updates from the LLS Beat AML Master Trial. Drs. Stock and Odenike talk with Dr. Ken Miller about determining a treatment plan for each patient, the role genetics and epigenetics may play, what the ultimate goals of care are, including...

Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR Recorded on December 14, 2020 What is follicular lymphoma and how does it differ from other indolent lymphomas? Can this cancer be cured? Join Dr. Ken Miller as he speaks with Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute and Medical Director of Hematology Research for The US Oncology Network to discuss this disease. Dr. Sharman reviews the current treatment options as well as upcoming treatment app...

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA Recorded on November 19, 2020 Morphology was once the only means of classifying blood cancers especially CLL; flow cytometry, cytogenetics and immunohistochemistry all followed. With a revolution in understanding, there is now a growing list of molecular tests that provide even more precise diagnostic and prognostic tools in diagnosis and treatment decisions. In this episode, Dr. Ken Miller speaks with Dr. Jennifer Brown from th...

Matthew B. Schabath, PhD, Moffitt Cancer Center, Tampa, FL Recorded on November 2, 2020 Individuals in the LGBTQI community face many barriers in accessing healthcare. In this episode, Dr. Matthew Schabath from the Moffitt Cancer Center addresses ways healthcare professionals can be more competent in supporting persons within this community. Dr. Schabath breaks down the terminology and stakeholders within this group to help make conversations comfortable and more productive with patients and t...

Gail J. Roboz, MD, Weill Cornell Medical College, New York, NY Recorded on October 2, 2020 Minimal/measurable residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. In this episode, Gail Roboz, MD, from Weill Cornell Medical College, provides an overview of MRD, including understanding its definition, explains the role advancements in technology have played in detection, and underscores the importance of understanding to what degree this dete...